Mu Epulo 2019, HopeMed adachita mgwirizano wapadziko lonse lapansi walayisensi ndi Bayer AG pakukula ndi kugulitsa kwa anti-monoclonal antibody yomwe imayang'ana pa PRL receptor pochiza tsitsi la abambo ndi amai, endometriosis, ndi matenda ena osachiritsika omwe ali ndi prolactin. (PRL) chizindikiro. Antibody iyi yawonetsa mikhalidwe yabwino kwambiri pazitsanzo za nyama kuphatikiza mitundu ya NHP ndi kafukufuku wachitetezo cha anthu. Chithandizo chake chazizindikiro ziwiri zazikulu, endometriosis ndi androgenetic alopecia, zonse zavomerezedwa ndi US FDA pamayesero azachipatala a Phase II. Mayesero achipatala a Phase II a HMI-115 mu endometriosis adayambitsa kale kulembetsa kwa odwala ku US kumapeto kwa 2021. Kuyesa kwake kwachipatala kwa Phase II kwa chithandizo cha androgenetic alopecia ndi chapadziko lonse lapansi chapakati, chosasinthika, chosawona kawiri, chopanda pake- maphunziro olamulidwa, omwe akukonzekera kuchitikira ku United States, Australia ndi mayiko ena.
Dr. Henri Doods, CEO wa HopeMed, anati "Ndine wonyadira kwambiri kuti FDA idavomerezanso IND yathu yachiwiri yomwe ndi yofunika kwambiri kwa kampani yathu yachinyamata. Ndi gawo lofunikira ku cholinga chathu chobweretsa zinthu zoyambira m'kalasi komanso zosiyanitsidwa kwambiri kwa odwala. Onse endometriosis ndi alopecia ndizizindikiro kumene odwala akudikirira mwachidwi njira zatsopano zochizira ndi kuchita bwino komanso chitetezo. Chipambano chokhala ndi zivomerezo ziwiri za IND m’kanthaŵi kochepa chotero ndi chilimbikitso kwa gulu lonse. Tadzipereka kwambiri kulimbikitsa ndi kukulitsa ntchito zathu za R&D kuti tibweretse njira zatsopano zothandizira odwala padziko lonse lapansi. ”